Solid Tumours

ESMO 2019


Expert interviews at ESMO 2019

Dr. Arkenau discusses combination studies of novel PARP inhibitors with other drugs.

Dr. Lordick on the use of anti-PD-1 and other emerging therapies in gastric and oesophageal cancers.

Dr. Möhler presents novel findings on anti-PD-1 therapies and explains differences regarding the outcome of anti-PD-1 therapies in Asian and Caucasian populations.

Dr. Chowdhury talks about the use of PARP inhibitors in prostate cancer as well as the impact of pamiparib in patients with advanced solid tumors.